Please login to the form below

Not currently logged in
Email:
Password:

nalmefene

This page shows the latest nalmefene news and features for those working in and with pharma, biotech and healthcare.

Acorda acquires Biotie to expand in Parkinson's disease

Acorda acquires Biotie to expand in Parkinson's disease

Biotie also has a royalty stream from Lundbeck's sales of Selincro(nalmefene), which was launched in 2013 for the treatment of alcohol dependency.

Latest news

More from news
Approximately 6 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2012 Pharma deals during September 2012

    The companies already have a worldwide exclusive licence agreement from 2006 for Selincro (nalmefene), a novel opioid system modulator to treat alcohol dependence.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics